These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26822531)

  • 1. The Optimal Duration of PTH(1-34) Infusion Is One Hour per Day to Increase Bone Mass in Rats.
    Shimizu M; Noda H; Joyashiki E; Nakagawa C; Asanuma K; Hayasaka A; Kato M; Nanami M; Inada M; Miyaura C; Tamura T
    Biol Pharm Bull; 2016; 39(4):625-30. PubMed ID: 26822531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion.
    Shen V; Birchman R; Wu DD; Lindsay R
    J Bone Miner Res; 2000 Apr; 15(4):740-6. PubMed ID: 10780865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.
    Ma YL; Cain RL; Halladay DL; Yang X; Zeng Q; Miles RR; Chandrasekhar S; Martin TJ; Onyia JE
    Endocrinology; 2001 Sep; 142(9):4047-54. PubMed ID: 11517184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.
    Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R
    J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent administration of parathyroid hormone (1-37) improves growth and bone mineral density in uremic rats.
    Schmitt CP; Hessing S; Oh J; Weber L; Ochlich P; Mehls O
    Kidney Int; 2000 Apr; 57(4):1484-92. PubMed ID: 10760084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone.
    Hock JM; Gera I
    J Bone Miner Res; 1992 Jan; 7(1):65-72. PubMed ID: 1532281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice.
    Iida-Klein A; Lu SS; Kapadia R; Burkhart M; Moreno A; Dempster DW; Lindsay R
    J Endocrinol; 2005 Sep; 186(3):549-57. PubMed ID: 16135674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intermittent administration of human parathyroid hormone on bone mineral density and arthritis in rats with collagen-induced arthritis.
    Fukata S; Hagino H; Okano T; Yamane I; Kameyama Y; Teshima R
    Arthritis Rheum; 2004 Dec; 50(12):4060-9. PubMed ID: 15593226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
    Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM
    J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH.
    Ueno Y; Shinki T; Nagai Y; Murayama H; Fujii K; Suda T
    J Cell Biochem; 2003 Oct; 90(2):267-77. PubMed ID: 14505343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.
    Smith BJ; Bu SY; Wang Y; Rendina E; Lim YF; Marlow D; Clarke SL; Cullen DM; Lucas EA
    Bone; 2014 Jan; 58():151-9. PubMed ID: 24125756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice.
    Pierroz DD; Bouxsein ML; Rizzoli R; Ferrari SL
    Bone; 2006 Aug; 39(2):260-7. PubMed ID: 16531131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.
    Greenspan SL; Holland S; Maitland-Ramsey L; Poku M; Freeman A; Yuan W; Kher U; Gertz B
    Proc Assoc Am Physicians; 1996 May; 108(3):230-8. PubMed ID: 8774056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat.
    Mitlak BH; Burdette-Miller P; Schoenfeld D; Neer RM
    J Bone Miner Res; 1996 Apr; 11(4):430-9. PubMed ID: 8992873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats.
    Meng XW; Liang XG; Birchman R; Wu DD; Dempster DW; Lindsay R; Shen V
    J Bone Miner Res; 1996 Apr; 11(4):421-9. PubMed ID: 8992872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenase-2 suppresses the anabolic response to PTH infusion in mice.
    Choudhary S; Canalis E; Estus T; Adams D; Pilbeam C
    PLoS One; 2015; 10(3):e0120164. PubMed ID: 25781979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of vitamin D and parathyroid hormone in the regulation of bone turnover and bone mass in men: the MINOS study.
    Szulc P; Munoz F; Marchand F; Chapuy MC; Delmas PD
    Calcif Tissue Int; 2003 Dec; 73(6):520-30. PubMed ID: 12958693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
    Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
    J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.